Overview

A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Status:
NOT_YET_RECRUITING

Trial end date:
2025-05-30

Target enrollment:

Participant gender:

Summary

This study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending doses (MAD) of SGB-3403 when single administered subcutaneously to healthy volunteers and multiple administered subcutaneously to subjects with elevated LDL-C to evaluate the safety, tolerance, PK, and PD.

Phase:

PHASE1

Details

Lead Sponsor:

Suzhou Sanegene Bio Inc.

Treatments:

Atorvastatin